Comparative transcriptomic and phenotypic analysis of induced pluripotent stem cell hepatocyte-like cells and primary human hepatocytes
AbstractPrimary human hepatocytes (PHHs) are used extensively for in vitro liver cultures to study hepatic functions. However, limited availability and invasive retrieval prevent their widespread use. Induced pluripotent stem cells exhibit significant potential since they can be obtained non-invasively and differentiated into hepatic lineages, such as hepatocyte-like cells (iHLCs). However, there are concerns about their fetal phenotypic characteristics and their hepatic functions compared to PHHs in culture. Therefore, we performed an RNA-sequencing (RNA-seq) analysis to understand pathways that are either up- or downregu...
Source: Cell and Tissue Research - February 19, 2024 Category: Cytology Source Type: research
Comparative transcriptomic and phenotypic analysis of induced pluripotent stem cell hepatocyte-like cells and primary human hepatocytes
Cell Tissue Res. 2024 Feb 19. doi: 10.1007/s00441-024-03868-9. Online ahead of print.ABSTRACTPrimary human hepatocytes (PHHs) are used extensively for in vitro liver cultures to study hepatic functions. However, limited availability and invasive retrieval prevent their widespread use. Induced pluripotent stem cells exhibit significant potential since they can be obtained non-invasively and differentiated into hepatic lineages, such as hepatocyte-like cells (iHLCs). However, there are concerns about their fetal phenotypic characteristics and their hepatic functions compared to PHHs in culture. Therefore, we performed an RNA...
Source: Cell Research - February 18, 2024 Category: Cytology Authors: Neeti Gandhi Lauren Wills Kyle Akers Yiqi Su Parker Niccum T M Murali Padmavathy Rajagopalan Source Type: research
“We agreed we would both die”: Navigating Ethical Complexities in Suicide Attempts in Older Adults
Mr. Smith was an 80-year-old man admitted to the inpatient medicine service following a suicide attempt by ingestion of an unknown amount of hydrocodone-acetaminophen and alcohol. The patient was transported by ambulance, accompanied by his daughter. His daughter was also his appointed medical power of attorney and had a copy of the patient's advance directive, where he had indicated his wish not to be resuscitated (DNR) in case of a life-threatening emergency.Soon after his arrival to the hospital, a dramatic series of events unfolded. (Source: The American Journal of Geriatric Psychiatry)
Source: The American Journal of Geriatric Psychiatry - February 18, 2024 Category: Geriatrics Authors: Michael Ward Source Type: research
Persistent Buccal Ulcer with Underlying Non-Neoplastic Ectopic Lymphoid Aggregates: A Tonsillar Tissue?
We presented a case of a 46-year-old woman from Saudi Arabia with a persistent buccal ulcer, measuring 0.4 × 0.4 × 0.3 cm. After surgical excision of the lesion was performed using both general and local anesthesia, its microscopic examination revealed keratinized squamous epithelium with surface ulcerations in the buccal mucosa. Beneath the epithelium, there was granulation tissue, scattered and clustered lymphoid tissue, and reactive germinal centers with tingible body microphages. These lymphoid clusters infiltrated the adjacent skeletal muscles and fat. The final diagnosis was ectopic oral tonsillar tissue ...
Source: Indian Journal of Otolaryngology and Head and Neck Surgery - February 16, 2024 Category: ENT & OMF Source Type: research
Safety of a 90-min duration of intravenous infusion of obinutuzumab in patients with B-cell non-Hodgkin's lymphoma in a tertiary hospital in China: a prospective, open-label, exploratory clinical trial
This study aimed to analyze the safety and applicability of a 90-min duration of infusion (SDI) of obinutuzumab in patients with B-cell non-Hodgkin's lymphoma (NHL) in a tertiary hospital in China. This exploratory clinical trial was performed at Jiangsu Province Hospital. All patients were treated with the standard infusion regimen for the first infusion. If no grade ≥3 infusion-related reactions (IRRs) occurred, the subsequent infusions were given as SDI. The primary endpoint was the incidence of IRR during the standard infusion (3-4 h) and 90-min SDI regimens. This study enrolled 208 patients and all completed cycle 1...
Source: Braz J Med Biol Res - February 15, 2024 Category: Research Authors: Shuangshuang Xing Yiqin Pu Xiaoqian Zhao Yan Hu Feiyan Zhang Zejuan Gu Wei Xu Lei Fan Yi Miao Jianyong Li Source Type: research
Safety of a 90-min duration of intravenous infusion of obinutuzumab in patients with B-cell non-Hodgkin's lymphoma in a tertiary hospital in China: a prospective, open-label, exploratory clinical trial
This study aimed to analyze the safety and applicability of a 90-min duration of infusion (SDI) of obinutuzumab in patients with B-cell non-Hodgkin's lymphoma (NHL) in a tertiary hospital in China. This exploratory clinical trial was performed at Jiangsu Province Hospital. All patients were treated with the standard infusion regimen for the first infusion. If no grade ≥3 infusion-related reactions (IRRs) occurred, the subsequent infusions were given as SDI. The primary endpoint was the incidence of IRR during the standard infusion (3-4 h) and 90-min SDI regimens. This study enrolled 208 patients and all completed cycle 1...
Source: Brazilian Journal of Medical and Biological Research - February 15, 2024 Category: Research Authors: Shuangshuang Xing Yiqin Pu Xiaoqian Zhao Yan Hu Feiyan Zhang Zejuan Gu Wei Xu Lei Fan Yi Miao Jianyong Li Source Type: research
Safety of a 90-min duration of intravenous infusion of obinutuzumab in patients with B-cell non-Hodgkin's lymphoma in a tertiary hospital in China: a prospective, open-label, exploratory clinical trial
This study aimed to analyze the safety and applicability of a 90-min duration of infusion (SDI) of obinutuzumab in patients with B-cell non-Hodgkin's lymphoma (NHL) in a tertiary hospital in China. This exploratory clinical trial was performed at Jiangsu Province Hospital. All patients were treated with the standard infusion regimen for the first infusion. If no grade ≥3 infusion-related reactions (IRRs) occurred, the subsequent infusions were given as SDI. The primary endpoint was the incidence of IRR during the standard infusion (3-4 h) and 90-min SDI regimens. This study enrolled 208 patients and all completed cycle 1...
Source: Cell Research - February 15, 2024 Category: Cytology Authors: Shuangshuang Xing Yiqin Pu Xiaoqian Zhao Yan Hu Feiyan Zhang Zejuan Gu Wei Xu Lei Fan Yi Miao Jianyong Li Source Type: research
Safety of a 90-min duration of intravenous infusion of obinutuzumab in patients with B-cell non-Hodgkin's lymphoma in a tertiary hospital in China: a prospective, open-label, exploratory clinical trial
This study aimed to analyze the safety and applicability of a 90-min duration of infusion (SDI) of obinutuzumab in patients with B-cell non-Hodgkin's lymphoma (NHL) in a tertiary hospital in China. This exploratory clinical trial was performed at Jiangsu Province Hospital. All patients were treated with the standard infusion regimen for the first infusion. If no grade ≥3 infusion-related reactions (IRRs) occurred, the subsequent infusions were given as SDI. The primary endpoint was the incidence of IRR during the standard infusion (3-4 h) and 90-min SDI regimens. This study enrolled 208 patients and all completed cycle 1...
Source: Braz J Med Biol Res - February 15, 2024 Category: Research Authors: Shuangshuang Xing Yiqin Pu Xiaoqian Zhao Yan Hu Feiyan Zhang Zejuan Gu Wei Xu Lei Fan Yi Miao Jianyong Li Source Type: research
Safety of a 90-min duration of intravenous infusion of obinutuzumab in patients with B-cell non-Hodgkin's lymphoma in a tertiary hospital in China: a prospective, open-label, exploratory clinical trial
This study aimed to analyze the safety and applicability of a 90-min duration of infusion (SDI) of obinutuzumab in patients with B-cell non-Hodgkin's lymphoma (NHL) in a tertiary hospital in China. This exploratory clinical trial was performed at Jiangsu Province Hospital. All patients were treated with the standard infusion regimen for the first infusion. If no grade ≥3 infusion-related reactions (IRRs) occurred, the subsequent infusions were given as SDI. The primary endpoint was the incidence of IRR during the standard infusion (3-4 h) and 90-min SDI regimens. This study enrolled 208 patients and all completed cycle 1...
Source: Brazilian Journal of Medical and Biological Research - February 15, 2024 Category: Research Authors: Shuangshuang Xing Yiqin Pu Xiaoqian Zhao Yan Hu Feiyan Zhang Zejuan Gu Wei Xu Lei Fan Yi Miao Jianyong Li Source Type: research
Safety of a 90-min duration of intravenous infusion of obinutuzumab in patients with B-cell non-Hodgkin's lymphoma in a tertiary hospital in China: a prospective, open-label, exploratory clinical trial
This study aimed to analyze the safety and applicability of a 90-min duration of infusion (SDI) of obinutuzumab in patients with B-cell non-Hodgkin's lymphoma (NHL) in a tertiary hospital in China. This exploratory clinical trial was performed at Jiangsu Province Hospital. All patients were treated with the standard infusion regimen for the first infusion. If no grade ≥3 infusion-related reactions (IRRs) occurred, the subsequent infusions were given as SDI. The primary endpoint was the incidence of IRR during the standard infusion (3-4 h) and 90-min SDI regimens. This study enrolled 208 patients and all completed cycle 1...
Source: Braz J Med Biol Res - February 15, 2024 Category: Research Authors: Shuangshuang Xing Yiqin Pu Xiaoqian Zhao Yan Hu Feiyan Zhang Zejuan Gu Wei Xu Lei Fan Yi Miao Jianyong Li Source Type: research
Safety of a 90-min duration of intravenous infusion of obinutuzumab in patients with B-cell non-Hodgkin's lymphoma in a tertiary hospital in China: a prospective, open-label, exploratory clinical trial
This study aimed to analyze the safety and applicability of a 90-min duration of infusion (SDI) of obinutuzumab in patients with B-cell non-Hodgkin's lymphoma (NHL) in a tertiary hospital in China. This exploratory clinical trial was performed at Jiangsu Province Hospital. All patients were treated with the standard infusion regimen for the first infusion. If no grade ≥3 infusion-related reactions (IRRs) occurred, the subsequent infusions were given as SDI. The primary endpoint was the incidence of IRR during the standard infusion (3-4 h) and 90-min SDI regimens. This study enrolled 208 patients and all completed cycle 1...
Source: Brazilian Journal of Medical and Biological Research - February 15, 2024 Category: Research Authors: Shuangshuang Xing Yiqin Pu Xiaoqian Zhao Yan Hu Feiyan Zhang Zejuan Gu Wei Xu Lei Fan Yi Miao Jianyong Li Source Type: research
Safety of a 90-min duration of intravenous infusion of obinutuzumab in patients with B-cell non-Hodgkin's lymphoma in a tertiary hospital in China: a prospective, open-label, exploratory clinical trial
This study aimed to analyze the safety and applicability of a 90-min duration of infusion (SDI) of obinutuzumab in patients with B-cell non-Hodgkin's lymphoma (NHL) in a tertiary hospital in China. This exploratory clinical trial was performed at Jiangsu Province Hospital. All patients were treated with the standard infusion regimen for the first infusion. If no grade ≥3 infusion-related reactions (IRRs) occurred, the subsequent infusions were given as SDI. The primary endpoint was the incidence of IRR during the standard infusion (3-4 h) and 90-min SDI regimens. This study enrolled 208 patients and all completed cycle 1...
Source: Braz J Med Biol Res - February 15, 2024 Category: Research Authors: Shuangshuang Xing Yiqin Pu Xiaoqian Zhao Yan Hu Feiyan Zhang Zejuan Gu Wei Xu Lei Fan Yi Miao Jianyong Li Source Type: research
Safety of a 90-min duration of intravenous infusion of obinutuzumab in patients with B-cell non-Hodgkin's lymphoma in a tertiary hospital in China: a prospective, open-label, exploratory clinical trial
This study aimed to analyze the safety and applicability of a 90-min duration of infusion (SDI) of obinutuzumab in patients with B-cell non-Hodgkin's lymphoma (NHL) in a tertiary hospital in China. This exploratory clinical trial was performed at Jiangsu Province Hospital. All patients were treated with the standard infusion regimen for the first infusion. If no grade ≥3 infusion-related reactions (IRRs) occurred, the subsequent infusions were given as SDI. The primary endpoint was the incidence of IRR during the standard infusion (3-4 h) and 90-min SDI regimens. This study enrolled 208 patients and all completed cycle 1...
Source: Brazilian Journal of Medical and Biological Research - February 15, 2024 Category: Research Authors: Shuangshuang Xing Yiqin Pu Xiaoqian Zhao Yan Hu Feiyan Zhang Zejuan Gu Wei Xu Lei Fan Yi Miao Jianyong Li Source Type: research
Safety of a 90-min duration of intravenous infusion of obinutuzumab in patients with B-cell non-Hodgkin's lymphoma in a tertiary hospital in China: a prospective, open-label, exploratory clinical trial
This study aimed to analyze the safety and applicability of a 90-min duration of infusion (SDI) of obinutuzumab in patients with B-cell non-Hodgkin's lymphoma (NHL) in a tertiary hospital in China. This exploratory clinical trial was performed at Jiangsu Province Hospital. All patients were treated with the standard infusion regimen for the first infusion. If no grade ≥3 infusion-related reactions (IRRs) occurred, the subsequent infusions were given as SDI. The primary endpoint was the incidence of IRR during the standard infusion (3-4 h) and 90-min SDI regimens. This study enrolled 208 patients and all completed cycle 1...
Source: Braz J Med Biol Res - February 15, 2024 Category: Research Authors: Shuangshuang Xing Yiqin Pu Xiaoqian Zhao Yan Hu Feiyan Zhang Zejuan Gu Wei Xu Lei Fan Yi Miao Jianyong Li Source Type: research
Safety of a 90-min duration of intravenous infusion of obinutuzumab in patients with B-cell non-Hodgkin's lymphoma in a tertiary hospital in China: a prospective, open-label, exploratory clinical trial
This study aimed to analyze the safety and applicability of a 90-min duration of infusion (SDI) of obinutuzumab in patients with B-cell non-Hodgkin's lymphoma (NHL) in a tertiary hospital in China. This exploratory clinical trial was performed at Jiangsu Province Hospital. All patients were treated with the standard infusion regimen for the first infusion. If no grade ≥3 infusion-related reactions (IRRs) occurred, the subsequent infusions were given as SDI. The primary endpoint was the incidence of IRR during the standard infusion (3-4 h) and 90-min SDI regimens. This study enrolled 208 patients and all completed cycle 1...
Source: Brazilian Journal of Medical and Biological Research - February 15, 2024 Category: Research Authors: Shuangshuang Xing Yiqin Pu Xiaoqian Zhao Yan Hu Feiyan Zhang Zejuan Gu Wei Xu Lei Fan Yi Miao Jianyong Li Source Type: research
